share_log

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024

Benzinga ·  Dec 29, 2023 20:04

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&A deals in Q3 2023.

PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: U.S. Deals 2024 Outlook. "As regulators' perspectives on key deal factors become better understood, there may be a return of larger deals, along with continued interest in the $5 billion to $15 billion deals to fill targeted strategic gaps."

"Despite some stabilization in the macroeconomic environment and the potential for a soft landing in sight, continued geopolitical and regulatory uncertainty seems a given in 2024," PWC added in its report.

The pharmaceutical and life sciences sector experienced a notably robust year in 2023, nearing pre-pandemic levels in both M&A deal value and volume, the PWC report added.

Anticipations for 2024 suggest continuing this trend, projecting comparable activity levels within the range of $225 billion to $275 billion across all subsectors.

Notable Deals in 2023

  • Pfizer Inc (NYSE:PFE) acquired Seagen Inc (NASDAQ:SGEN) for $43 billion.
  • Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc KRTX for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • Merck & Co (NYSE:MRK) acquired Prometheus Biosciences for $200.00 per share in cash for a total equity value of ~$10.8 billion.
  • AbbVie Inc (NYSE:ABBV) to acquire ImmunoGen Inc (NASDAQ:IMGN) and its flagship cancer therapy Elahere, for $31.26 per share in cash. The transaction values ImmunoGen at a total equity value of approximately $10.1 billion.
  • AbbVie Inc (NYSE:ABBV) will acquire psychiatric and neurological disorders player Cerevel Therapeutics Holdings, Inc (NASDAQ: CERE) for $45 per share in cash with a total equity value of approximately $8.7 billion.
  • Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.
  • Bristol Myers Squibb & Co (NYSE: BMY) agreed to purchase Mirati Therapeutics Inc (NASDAQ: MRTX) at $58.00 per share in cash, amounting to an overall equity valuation of $4.8 billion, with an additional Contingent Value Right at $12.00 per share in cash, offering an extra $1.0 billion in value opportunity.
  • Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of approximately $5.9 billion.
  • Most recently, Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
  • Image by Steve Buissinne from Pixabay
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment